Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kodiak Sciences Inc.KOD · Entity 4388 | Director | June 30, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kodiak Sciences Inc.
Report date June 30, 2026 · Filed July 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.96 · Expires 2036-06-29 | Direct | 17,731 |
Reported balance
After 2026-06-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-30 · Grant · Acquired 17,731 · Balance 17,731 F1: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One hundred percent (100%) of the shares subject to the option shall vest upon the earlier of June 30, 2027 or one (1) day prior to the Issuer's next annual meeting occurring after the grant date, in each case, provided the Reporting Person continues to serve as a member of the Issuer's board of directors through the applicable vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
GILEAD SCIENCES, INC.
Report date May 08, 2007 · Filed May 15, 2007
Section 16 reporting ended · disclosed 2007-05-15. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Kronos Bio, Inc.
Report date June 20, 2025 · Filed June 20, 2025
Section 16 reporting ended · disclosed 2025-06-20. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 1
1 source rowRow 1 · 2025-06-20 · Other · Disposed 11,333 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2] F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.58 · Expires 2031-03-24 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-20 · Disposition to issuer · Disposed 41,200 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.18 · Expires 2031-06-21 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-06-20 · Disposition to issuer · Disposed 5,150 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.53 · Expires 2032-06-21 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-06-20 · Disposition to issuer · Disposed 17,000 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2033-06-21 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-06-20 · Disposition to issuer · Disposed 34,000 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.95 · Expires 2034-06-24 | Direct | 0 |
Reported balance
After 2025-06-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-06-20 · Disposition to issuer · Disposed 34,000 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 1, 2025, by and among Kronos Bio, Inc. (the "Issuer"), Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub IV, Inc., a wholly owned subsidiary of Parent ("Merger Sub"). On June 18, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $0.57 per Share in cash (the "Cash Amount"), and (ii) one non-transferable contractual contingent value right (each, a "CVR"), subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price").[continues to Footnote 2]
F2: [continues from Footnote 1] Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.
F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option; provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount that was then outstanding it was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 862 | $0.00 Strike: $16.44 | $0.00 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · derivative · entry 21 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,586 Underlying: Common Stock · 862 shares Expires 2012-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: Options vested 20% on the January 30, 2003, the first anniversary date of the grant. The balance vested every three months thereafter and was fully vested at January 30, 2007. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,888 | $0.00 Strike: $11.76 | $0.00 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · derivative · entry 20 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,888 shares Expires 2010-11-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Options vested 20% on the November 8, 2001, the first anniversary date of the grant. The balance vested every three months thereafter and was fully vested at November 8, 2005. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $9.81 | $0.00 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · derivative · entry 19 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 1,000 shares Expires 2011-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: Options vested 20% on the April 18, 2002, the first anniversary date of the grant. The balance vested every three months thereafter and was fully vested at April 18, 2006. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $9.34 | $0.00 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · derivative · entry 18 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires 2010-07-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Options vested 20% on the July 20, 2001, the first anniversary date of the grant. The balance vested every three months thereafter and was fully vested at July 20, 2005. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 4,800 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · derivative · entry 17 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,800 shares Expires 2010-04-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Options vested 20% on the April 5, 2001, the first anniversary date of the grant. The balance vested every three months thereafter and was fully vested at April 5, 2005. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 3,208 | $0.00 Strike: $7.40 | $0.00 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · derivative · entry 16 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,208 shares Expires 2001-01-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Options vested 20% on the January 18, 2002, the first anniversary date of the grant. The balance vested every three months thereafter and was fully vested at January 18, 2006. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 11,624 | $0.00 Strike: $7.30 | $0.00 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · derivative · entry 15 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,624 shares Expires 2009-07-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Options vested 20% on the July 22, 2000, the first anniversary date of the grant. The balance vested every three months thereafter and was fully vested at July 22, 2004. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $7.08 | $0.00 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · derivative · entry 14 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2010-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Options vested 20% on the January 26, 2001, the first anniversary date of the grant. The balance vested every three months thereafter and was fully vested at January 26, 2005. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 58,664 | $0.00 Strike: $4.47 | $0.00 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · derivative · entry 13 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 58,664 shares Expires 2009-01-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vested 20% on the January 26, 2000, the first anniversary date of the grant. The balance vested every three months thereafter and was fully vested at January 26, 2004. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $2.86 | $0.00 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · derivative · entry 12 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2008-07-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Options vested 20% on the July 23, 1999, the first anniversary date of the grant. The balance vested every three months thereafter and was fully vested at July 23, 2003. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 862 | $16.44 | $14,169.13 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · nonDerivative · entry 10 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,661 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,000 | $9.81 | $9,810.00 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · nonDerivative · entry 9 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 224,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,208 | $7.40 | $23,734.39 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · nonDerivative · entry 8 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 1,888 | $11.76 | $22,198.92 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · nonDerivative · entry 7 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 11,624 | $7.30 | $84,819.17 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · nonDerivative · entry 6 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 3,000 | $9.34 | $28,031.40 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · nonDerivative · entry 5 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 207,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 4,800 | $7.41 | $35,550.24 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · nonDerivative · entry 4 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,079 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 2,000 | $7.08 | $14,156.40 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · nonDerivative · entry 3 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 58,664 | $4.47 | $262,157.68 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · nonDerivative · entry 2 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,279 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 13, 2006 Filed Feb 15, 2006 22:50 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 12,000 | $2.86 | $34,312.80 |
DisclosureSEC source: 0001179110-06-004011 · edgar.xml · nonDerivative · entry 1 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 25, 2006 Filed Jan 28, 2006 00:57 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-qualified Stock Option (right to buy) · Derivative | 65,000 | $0.00 Strike: $58.01 | $0.00 |
DisclosureSEC source: 0001179110-06-002227 · edgar.xml · derivative · entry 1 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2016-01-25 F1 · derivative.exercise_date: The options have a five year vesting schedule. 20% of the options will vest on January 25, 2007, the first anniversary date of the grant. The balance will vest 5% every three months thereafter until fully vested on January 25, 2011. Read SEC document |
| November 22, 2005 Filed Nov 24, 2005 01:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $54.12 | $27,060.00 |
DisclosureSEC source: 0001179110-05-021775 · edgar.xml · nonDerivative · entry 12 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,615 Read SEC document |
| November 22, 2005 Filed Nov 24, 2005 01:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $54.07 | $10,814.00 |
DisclosureSEC source: 0001179110-05-021775 · edgar.xml · nonDerivative · entry 11 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,115 Read SEC document |
| November 22, 2005 Filed Nov 24, 2005 01:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,900 | $54.04 | $102,676.00 |
DisclosureSEC source: 0001179110-05-021775 · edgar.xml · nonDerivative · entry 10 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,315 Read SEC document |
| November 22, 2005 Filed Nov 24, 2005 01:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $54.05 | $108,100.00 |
DisclosureSEC source: 0001179110-05-021775 · edgar.xml · nonDerivative · entry 9 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,215 Read SEC document |
| November 22, 2005 Filed Nov 24, 2005 01:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 600 | $54.03 | $32,418.00 |
DisclosureSEC source: 0001179110-05-021775 · edgar.xml · nonDerivative · entry 8 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,215 Read SEC document |
| November 22, 2005 Filed Nov 24, 2005 01:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 200 | $54.00 | $10,800.00 |
DisclosureSEC source: 0001179110-05-021775 · edgar.xml · nonDerivative · entry 7 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,815 Read SEC document |
| November 22, 2005 Filed Nov 24, 2005 01:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 712 | $54.02 | $38,462.24 |
DisclosureSEC source: 0001179110-05-021775 · edgar.xml · nonDerivative · entry 6 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,015 Read SEC document |
| November 22, 2005 Filed Nov 24, 2005 01:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 600 | $53.99 | $32,394.00 |
DisclosureSEC source: 0001179110-05-021775 · edgar.xml · nonDerivative · entry 5 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,727 Read SEC document |
| November 22, 2005 Filed Nov 24, 2005 01:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 400 | $54.01 | $21,604.00 |
DisclosureSEC source: 0001179110-05-021775 · edgar.xml · nonDerivative · entry 4 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,327 Read SEC document |
| November 22, 2005 Filed Nov 24, 2005 01:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 688 | $53.97 | $37,131.36 |
DisclosureSEC source: 0001179110-05-021775 · edgar.xml · nonDerivative · entry 3 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,727 Read SEC document |
| November 22, 2005 Filed Nov 24, 2005 01:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 900 | $53.95 | $48,555.00 |
DisclosureSEC source: 0001179110-05-021775 · edgar.xml · nonDerivative · entry 2 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,415 Read SEC document |
| November 22, 2005 Filed Nov 24, 2005 01:26 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 11,300 | $53.96 | $609,748.00 |
DisclosureSEC source: 0001179110-05-021775 · edgar.xml · nonDerivative · entry 1 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,315 Read SEC document |
| August 31, 2005 Filed Sep 1, 2005 01:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 400 | $42.08 | $16,832.00 |
DisclosureSEC source: 0001179110-05-017259 · edgar.xml · nonDerivative · entry 8 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,615 Read SEC document |
| August 31, 2005 Filed Sep 1, 2005 01:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 300 | $42.06 | $12,618.00 |
DisclosureSEC source: 0001179110-05-017259 · edgar.xml · nonDerivative · entry 7 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,015 Read SEC document |
| August 31, 2005 Filed Sep 1, 2005 01:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,800 | $42.07 | $159,866.00 |
DisclosureSEC source: 0001179110-05-017259 · edgar.xml · nonDerivative · entry 6 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,315 Read SEC document |
| August 31, 2005 Filed Sep 1, 2005 01:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,000 | $42.11 | $42,110.00 |
DisclosureSEC source: 0001179110-05-017259 · edgar.xml · nonDerivative · entry 5 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,115 Read SEC document |
| August 31, 2005 Filed Sep 1, 2005 01:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 1,500 | $42.12 | $63,180.00 |
DisclosureSEC source: 0001179110-05-017259 · edgar.xml · nonDerivative · entry 4 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,115 Read SEC document |
| August 31, 2005 Filed Sep 1, 2005 01:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $42.14 | $84,280.00 |
DisclosureSEC source: 0001179110-05-017259 · edgar.xml · nonDerivative · entry 3 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,615 Read SEC document |
| August 31, 2005 Filed Sep 1, 2005 01:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $42.16 | $21,080.00 |
DisclosureSEC source: 0001179110-05-017259 · edgar.xml · nonDerivative · entry 2 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,615 Read SEC document |
| August 31, 2005 Filed Sep 1, 2005 01:23 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 500 | $42.14 | $21,070.05 |
DisclosureSEC source: 0001179110-05-017259 · edgar.xml · nonDerivative · entry 1 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,115 Read SEC document |
| July 27, 2005 Filed Jul 30, 2005 00:37 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $43.97 | $0.00 |
DisclosureSEC source: 0001179110-05-015038 · edgar.xml · derivative · entry 1 YANG TAIYIN · CIK 0001334505 · SVP, Pharm Dev & Mfg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2015-07-27 F1 · derivative.exercise_date: Options will vest 20% on July 27, 2006, the first anniversary date of the grant. The remaining balance will vest quarterly over the next four years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.